Immunoprecise to Acquire Crossbeta Biosciences
Immunoprecise ("the Company") announces that it has signed a binding letter of intent with Crossbeta Biosciences B.V. whereby the Company has agreed to acquire all of the issued and outstanding shares of Crossbeta (the “Transaction”).
The Transaction continues to realize on the Board’s commitment to grow globally through strategic acquisitions. It allows IPA to build a pipeline of antibodies with application in biomarker/diagnostic assays and as therapeutics and thereby significantly extends its ambition of becoming a single source provider of services across the full antibody discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and to offer the full spectrum of antibody production methodologies (library based technologies, hybridoma methods, transgenic animal based platforms and single B cell based technology).
Furthermore, the acquisition enhances the Company’s source of and capacity for developing unique antigens for generating and selecting antibodies. “In acquiring Crossbeta Biosciences B.V., IPA becomes a leading integrated antibody solutions company with high value potential biomarker/diagnostic and therapeutic assets” said Dr. James Kuo, Chairman, Interim President of the Company.
“In acquiring Crossbeta Biosciences B.V., IPA becomes a leading integrated antibody solutions company with high value potential biomarker/diagnostic and therapeutic assets” said Dr. James Kuo, Chairman, Interim President of the Company.
Probiodrug en Crossbeta blijven samenwerken (bericht dd 5 december jl.) ze verlengen de samenwerking o.v.k. Probiodrug maakt gebruik van technologie die ontwikkeld is door het Nederlandse Crossbeta.
Het samenwerkingsprogramma heeft tot dusver prima resultaten opgeleverd en heeft voldaan aan alle belangrijke doelstellingen, aldus Probiodrug.